Health
Personalised mRNA Cancer Vaccine Meets Key Goals in Phase 3 Melanoma Trial
Moderna and Merck say their personalised mRNA therapy, combined with Keytruda, met the main goals of a large Phase 3 melanoma study. Here is what the result means—and what remains unknown.
